{"classes":[{"categories":[{"measurements":[{"comment":"Not enough events to calculate the data.","groupId":"OG000","lowerLimit":"1.45","upperLimit":"NA","value":"4.17"},{"comment":"Not enough events to calculate the data.","groupId":"OG001","lowerLimit":"1.28","upperLimit":"NA","value":"7.66"},{"comment":"Not enough events to calculate the data.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Not enough events to calculate the data.","groupId":"OG003","lowerLimit":"1.35","upperLimit":"NA","value":"8.28"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"}],"units":"Participants"}],"description":"Progression-free survival (PFS) defined as time from first treatment (AFM13/AB-101) received until progressive disease (PD). Subjects who started a new anti-lymphoma therapy prior to a documented progressive disease were censored at the last disease assessment prior to initiation of new anti-lymphoma therapy. Subjects who discontinued the study before the first assessment of progressive disease or death were censored at their last disease assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cohort 1: 200 mg AFM13 + AB-101 (2 × 10e9 cells on Day 1, Day 8, Day 15)\n\nAFM13: anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion\n\nAB-101: NK cell therapy, intravenous infusion\n\nCyclophosphamide: Lymphodepleting chemotherapy, intravenous infusion\n\nFludarabine: Lymphodepleting chemotherapy, intravenous infusion\n\nInterleukin-2: Immune cytokine, subcutaneously","id":"OG000","title":"Safety run-in Cohort 1"},{"description":"Cohort 2: 300 mg AFM13 + AB-101 (2 × 10e9 cells on Day 1, Day 8, Day 15)\n\nAFM13: anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion\n\nAB-101: NK cell therapy, intravenous infusion\n\nCyclophosphamide: Lymphodepleting chemotherapy, intravenous infusion\n\nFludarabine: Lymphodepleting chemotherapy, intravenous infusion\n\nInterleukin-2: Immune cytokine, subcutaneously","id":"OG001","title":"Safety run-in Cohort 2"},{"description":"Cohort 3: 200 mg AFM13 + AB-101 (4 × 10e9 cells on Day 1; 2 × 10e9 cells on Day 8, Day 15)\n\nAFM13: anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion\n\nAB-101: NK cell therapy, intravenous infusion\n\nCyclophosphamide: Lymphodepleting chemotherapy, intravenous infusion\n\nFludarabine: Lymphodepleting chemotherapy, intravenous infusion\n\nInterleukin-2: Immune cytokine, subcutaneously","id":"OG002","title":"Safety run-in Cohort 3"},{"description":"Cohort 4: 300 mg AFM13 + AB-101 (4 × 10e9 cells on Day 1; 2 × 10e9 cells on Day 8, Day 15)\n\nAFM13: anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion\n\nAB-101: NK cell therapy, intravenous infusion\n\nCyclophosphamide: Lymphodepleting chemotherapy, intravenous infusion\n\nFludarabine: Lymphodepleting chemotherapy, intravenous infusion\n\nInterleukin-2: Immune cytokine, subcutaneously","id":"OG003","title":"Safety run-in Cohort 4"}],"paramType":"MEDIAN","populationDescription":"The Safety Run In Set (SRI) consists of all subjects of the 4 safety run-in cohorts who have received at least 66% of the combination dose during Cycle 1.","reportingStatus":"POSTED","timeFrame":"From the first treatment received until the first progression disease assessed by IRC or death.","title":"Progression-free Survival (PFS) by Independent Radiology Committee","type":"SECONDARY","unitOfMeasure":"months"}